Retrospective Study
Copyright ©The Author(s) 2025.
World J Gastrointest Oncol. Jun 15, 2025; 17(6): 107980
Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.107980
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Flow chart of the screening process for advanced gastric cancer patients receiving immunotherapy combined with chemotherapy. PD-1: Programmed cell death protein 1; PD-L1: Programmed cell death ligand 1; FAR: Fibrinogen-to-albumin ratio.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Receiver operating characteristics curve analysis based on fibrinogen to albumin ratio for overall survival. AUC: Area under the curve.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Effects of different fibrinogen to albumin on the long-term prognosis of gastric cancer patients. A: Kaplan-Meier plot of the fibrinogen-to-albumin ratio (FAR) < 0.08 and FAR ≥ 0.08 groups; B: Kaplan-Meier plot of overall survival in the FAR < 0.08 and FAR ≥ 0.08 groups. FAR: Fibrinogen-to-albumin ratio; HR: Hazard ratio.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Graph depicting the prognostic model for predicting 12-, 15-, and 18-month overall survival. ECOG: Eastern Cooperative Oncology Group; FAR: Fibrinogen-to-albumin ratio; BMI: Body mass index; PD-L1: Programmed cell death ligand 1; OS: Overall survival.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Graph depicting the operating characteristic evaluation plot for a prognostic model. A: Graph showing the training set and validation set receiver operating characteristic (ROC) evaluation plots for 12-month prognostic prediction model; B: Graph showing the training set and validation set ROC evaluation plots for 15-month prognostic prediction model; C: Graph showing the training set and validation set ROC evaluation plots for 18-month prognostic prediction model. AUC: Area under the curve.
Figure 6
Open in New Tab Full Size Figure Download Figure
Figure 6 Graph illustrating the calibration plots for a prognostic model. A: Calibration plots for the training set 12-month overall survival (OS); B: Calibration plots for the validation set 12-month OS; C: Calibration plots for the training set 15-month OS; D: Calibration plots for the validation set 15-month OS; E: Calibration plots for the training set 18-month OS; F: Calibration plots for the validation set 18-month OS.